Through researching human biology, our scientists identify targets that can be linked to the onset, progression or even prevention of a disease. After a target is identified, it is often validated through further research in animal models.
Regeneron’s process starts with our deep belief in the power of genetics and our fundamental understanding of basic biology. In the early 2000s, we generated one of the first “knockout” mice in biotech history, which allowed us to study how certain genes (or the absence of certain genes) affect health and disease.
Our continued leadership in mouse genetics capabilities – a key stepping stone for the development of antibody medicines – resulted in the development of our VelociSuite® technologies, starting with VelociGene® and VelociMouse® for superior disease modeling and target exploration.
We continue to push the frontiers of genetics research with the Regeneron Genetics Center® (RGC)– one of the largest and most ambitious efforts to pair human DNA sequences with deidentified health records to find rare people who are resistant to disease so that we can identify new drug targets and facilitate better treatments.